SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells

Abstract

In this report, we show that malignant pleural mesothelioma (MPM) patients whose tumors express high levels of AKT1 exhibit a significantly worse prognosis, whereas no significant correlation with AKT3 expression is observed. We provide data that establish a phosphorylation independent role of AKT1 in affecting MPM cell shape and anchorage independent cell growth in vitro and highlight the AKT1 isoform-specific nature of these effects.We describe that AKT1 activity is inhibited by the loss of SIRT1-mediated deacetylation and identify, by mass spectrometry, 11 unique proteins that interact with acetylated AKT1.Our data demonstrate a role of the AKT1/SIRT1/FOXM1 axis in the expression of the tumor suppressor ERβ. We further demonstrate an inhibitory feedback loop by ERβ, activated by the selective agonist KB9520, on this axis both in vitro and in vivo.Our data broaden the current knowledge of ERβ and AKT isoform-specific functions that could be valuable in the design of novel and effective therapeutic strategies for MPM.

DOI: 10.18632/oncotarget.7321

Extracted Key Phrases

Cite this paper

@inproceedings{Pinton2016SIRT1AT, title={SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells}, author={Giulia Pinton and Sara Zonca and Arcangela Gabriella Manente and Maria Cavaletto and Ester Borroni and Antonio Daga and Puthen V. Jithesh and Dean Andrew Fennell and Stefan Nilsson and Laura Moro}, booktitle={Oncotarget}, year={2016} }